On April 16, 2026 Elephas Biosciences Corporation (Elephas), a private company that has developed the elive ex vivo tumor profiling platform, reported a scientific collaboration with Mithrl, an AI company focused on accelerating research through its Scientific Decision Engine (SDE). Combining these innovative approaches establishes a foundation for integrating functional tumor profiling with AI-driven analysis to support more scalable and systematic discovery of novel immunotherapy response signals.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Elephas elive platform captures real-time cytokine responses from live tumor fragments of core needle biopsies. Pairing the elive platform with Mithrl’s SDE enables autonomous design and execution of multi-step scientific analyses under rigorous controls.
Along with Mithrl, Elephas will be co-presenting new data from this collaboration at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, highlighting the potential of combining real-time functional tumor profiling with multi-modal data analysis to generate biologically meaningful insights more efficiently.
Poster Presentation: Multi-agent-augmented analysis of PD-1 checkpoint inhibitor response (Abstract #5695)
Date/Time: April 20, 2026, 9:00 AM – 12:00 PM PST
Location: Section 40
Learn more on the poster here: View Source!/21436/presentation/9781
"Partnering with Mithrl enables us to more fully leverage the richness of our functional profiling data and showcase the power of Agentic AI," said Hinco Gierman, CSO of Elephas. "By integrating these data with external datasets, we’re incredibly impressed with the speed at which Mithrl is able to generate novel insights that can better understand the biology of response and generate insights that may help guide translational research and therapeutic development."
"Collaborating with Elephas allows us to pair their unprecedented real-time tumor profiling from live tumor biopsies with Mithrl’s SDE to unlock deep biological insights that would otherwise remain elusive or take months to surface. I believe this combination exemplifies the future of translational research," said Vivek Adarsh, Co-Founder and CEO of Mithrl.
(Press release, Elephas Biosciences, APR 16, 2026, View Source [SID1234664445])